background As loss from HIV care is an ongoing challenge globally, interventions are needed for patients who don't achieve or maintain ART stability. The 2015 South African National Adherence Guidelines (AGL) for Chronic Diseases include two interventions targeted at unstable patients: early tracing of patients who miss visits (TRIC) and enhanced adherence counselling (EAC).
Introduction

Background
The majority of patients who initiate antiretroviral therapy (ART) suppress the virus to undetectable levels, leading to a dramatically increased life expectancy [1] [2] [3] [4] and reduced morbidity [5, 6] . Some of those who initiate HIV treatment, however, either cannot reach viral suppression targets or, after achieving suppression, cannot sustain it over time. Still other patients who initiate HIV treatment leave HIV care altogether [7] [8] [9] [10] [11] [12] , putting them at risk for poor health outcomes, death, development of viral resistance, and onwards transmission to uninfected partners [13, 14] . If international goals aimed at ending transmission [15] and preventing AIDS-related deaths are to be achieved, these 'unstable' patients will require effective targeted interventions aimed at improving adherence to HIV treatment and increasing retention in care.
South Africa has the greatest number of HIV infected people in the world and also has the largest HIV care and treatment programme. While the national HIV response has led to significant gains in life expectancy, rates of retention in care, ART adherence, and viral suppression are not optimal [16] [17] [18] . Unless these issues can be addressed, South Africa risks not reaching its target of 90% of those infected on treatment and 90% of those on treatment virally suppressed. Recognising this, South Africa's National Department of Health (NDOH) has developed a set of National Adherence Guidelines [19] (AGL) that call for utilisation of a package of interventions within public sector clinics to increase rates of HIV treatment initiation, retention, and viral suppression. These interventions fall under the rubric of 'differentiated care' [20] [21] [22] [23] , in which different models of HIV service delivery are tailored to specific subsets of the treatment population (e.g. those newly initiating, those stable on treatment, and those unstable on treatment). Prior to national AGL adoption, South Africa's NDOH piloted the package of interventions in 12 primary health care clinics and community health centres randomly chosen from among 24 pilot facilities, providing a comparison population within which to assess the effectiveness of interventions supported by the AGL.
In this manuscript, we evaluate the effectiveness of two of the AGL interventions that were specifically targeted at patients on ART who were considered unstable, either because they were not virally suppressed or because they had missed clinic visits. We determined whether Early Patient Tracing for patients who had missed a scheduled appointment was effective at returning patients to care and whether Enhanced Adherence Counselling was effective in achieving viral suppression for those found unsuppressed.
Methods
Study design
Details of the evaluation methodology have been published elsewhere [24] . We conducted a pragmatic evaluation of a cluster-randomised roll-out of the interventions delivered by selected NDOH clinics in four provinces in South Africa (Gauteng, KwaZulu Natal, Limpopo and North West). Prior to implementation 24 high-volume clinics (clusters) that all collected electronic medical record data (TIER.Net) were matched as pairs on district, clinic size (as measured by total on ART), proportion of patients virally suppressed, setting (rural/urban/formal/informal), and location (sites near each other). Within each pair, computer randomisation was used to allocate one to be an intervention site and implement the package of interventions and the other to be a control site, with delayed implementation of the interventions. To do so, an excel spreadsheet with each matched pair was created and we used a random number generator to allocate one site to intervention and one to control.
Interventions
We report here on the two AGL interventions targeted at unstable patients, Enhanced Adherence Counselling (EAC) for those with an elevated viral load (>400 copies/ ml) and Early Tracing and Retention in Care of patients (TRIC) for those who missed a visit by 5 to 90 days. These were supposed to be implemented according to the AGLs' Standard Operating Procedures [25] , which provided detailed instructions to the sites for each intervention.
Enhanced adherence counselling provides targeted adherence counselling to ART patients who have poor treatment adherence, as indicated by an elevated viral load, to help them improve their adherence. This intervention standardises and intensifies the counselling that ART patients with detectable viral loads receive under standard of care. The intervention provides one additional, intensive counselling session, and a second if abnormal results continue after session one. These are structured education/counselling sessions in which effective strategies for achieving good adherence and for overcoming adherence barriers are discussed, and goals set for viral resuppression. Therefore, after an elevated viral load, clinicians work with patients to understand their results and to identify whether any side effects are occurring as well as whether or not their treatment regimen should be changed. Counsellors and nurses provide the counselling by providing education, reviewing and addressing barriers to adherence and setting goals with the patients.
Tracing and retention in care identifies patients who have not returned to the clinic for scheduled appointments and attempts to bring them back into care. It also requires maintaining an electronic medical record to ensure that missed visits are accurately detected. The goal is to reduce loss to follow-up and improve patient outcomes by identifying those who have missed appointments and seeking to encourage them to return to care. Success requires maintaining up-to-date contact information in patient records. Tracing is done by outreach workers who receive a list of patients who are late for appointments or lost to follow-up. Initial attempts are made to phone the patient. If they cannot be reached, home visits are then attempted when possible.
Both interventions were implemented by the facilities' health staff. Some training and materials were provided by the respective Departments of Health, but there was little ongoing mentoring or in-service training or support for the interventions. In particular, little oversight was provided on the selection of individual patients eligible for the interventions, nor did the clinic staff receive feedback on the quality or outcomes of the interventions.
Eligibility criteria
The evaluation included HIV-positive patients ≥18 years old who initiated first-line ART. We did not restrict to any specific amount of time on treatment. As these were patients who were found unstable in care in routine monitoring, they were likely patients who had been on treatment for some time. We excluded patients not resident in the facility's catchment area, those who intended to transfer care to a different facility (as noted in their clinic files) or who were eligible for prevention of mother-tochild transmission services because they were pregnant. We excluded pregnant women because we felt that patterns of attrition from HIV care for pregnant women differ from the general population and we did not have a sufficient number to be able to say anything specific about them. The EAC eligible population was limited to those on ART for ≥3 months and had documented poor adherence (elevated viral load >400 copies/ml). The TRIC population was limited to those who failed to return for a scheduled appointment within 5 to 90 days from their scheduled appointment date.
Enrolment
The AGL interventions were implemented by regular clinic staff as routine care in the 12 intervention clinics. For the evaluation, a waiver of consent was granted and no patient contact occurred as contact with patients would likely have changed retention outcomes. Instead, we included patients who met the inclusion criteria between June 20th and December 16th, 2016. We identified potentially eligible subjects by analysing electronic medical record data to determine patients who met the criteria for each specific intervention. At intervention sites, we identified patients whose most recent viral load was unsuppressed (>400 copies/ml) for the EAC cohort, and those who missed a scheduled visit between 5 and 90 days for the TRIC cohort and then determined which patients received the intervention. We enrolled those who were eligible and received the intervention (for EAC as identified from a facility register or inclusion of an adherence plan in the patient file; for TRIC from a tracing register). At control sites we enrolled patients who would have been eligible for the interventions, had they been implemented.
Study outcomes
We report here on both short-term and final outcomes. For EAC, the primary short-term outcome was viral load resuppression (<400 copies/ml) at any time within 3 months of EAC eligibility among all enrolled subjects (i.e. intention-to-treat) as evidenced by a viral load in clinical records. Under current guidelines, patients with a detectable viral load above 1000 copies/ml are asked to return 2 months later for a second viral load, to determine whether they have re-supressed. The final outcomes were viral suppression and retention (as defined by clinical records) within 12 months (defined as within 2 to 18 months of eligibility). For TRIC, primary outcomes were return to care within 3 months of TRIC eligibility among all enrolled subjects as evidenced by a visit recorded in the clinical records and retention within 12 months. This was time from tracing attempt or eligibility for tracing attempt in the control arm. Follow-up data were collected from clinic files, patient registers, electronic patient records, and the National Health Laboratory Service (NHLS) database.
Analytic methods
Our sample size calculations used alpha = 0.05, power = 80% and a coefficient of variation = 0.1. We based the sample size calculation on data from South African health facilities where we conduct research [17, [26] [27] [28] . For EAC, we anticipated 52% of patients with an elevated viral load resuppress after one counselling session. We anticipated we would need 42 subjects per clinic (1008 patients total) to detect a 15% difference. For TRIC, clinic data suggested 20%-35% of patients lost from care return with little intervention [7, 8] . We anticipated needing 24 subjects per clinic (576 patients total) to detect a 15% difference assuming 30% baseline loss to follow-up.
For all outcomes, we compared intervention and control groups and estimated risk differences (RD) and 95% confidence intervals (CI). We adjusted for clustering using a linear regression generalised estimating equation (GEE) with an unstructured correlation matrix with the outcome as a linear function of being in the intervention arm (vs. control) adjusted for baseline confounding variables. Potential confounders included age, sex, log viral load, baseline CD4 count and WHO stage.
We further controlled for baseline imbalances using a difference-in-differences design [29] . We compared differences in outcomes between arms both before and after the intervention period and estimated treatment effects as the difference between the two. For the control period, we included data on patients from 1 January 2015 through 31 December 2015 (called 'preperiod'). For the intervention period we included data on all enrolled patients. We conducted an additional intervention period analysis using electronic medical record data where we included all patients at the clinic who were eligible for the early tracing intervention from 1 March 2016 through 30 September 2016. Our regression model was:
where outcome ij represents the relevant binary outcome for the ith person in time period j, period is an indicator for the time period (1 = intervention period, 0 = preintervention) and group is an indicator for treatment arm (0 = control, 1 = intervention). b 3 (the coefficient for the interaction between period and intervention) estimates the effect of the intervention adjusted for baseline differences in the outcome. We further controlled for any measured confounders (X ij ).
Ethical considerations
Both the Human Research Ethics Committee of the University of the Witwatersrand and the Boston University Institutional Review Board approved use of routine data and a waiver of consent. The trial was registered at clinicaltrials.gov (NCT02536768).
Results
Enhanced adherence counselling
For EAC evaluation, we enrolled 358 intervention and 505 control subjects. Patients were evenly divided between those below and above 40 years (50%), 60% were female, and the median CD4 count at initiation was 157 cells/ml. Intervention and control cohorts were well balanced with respect to age, sex, and tuberculosis at enrolment (Table 1) . There were small differences between control and intervention in median CD4 count (160 vs. 144 cells/ml respectively) and log viral load (log 10 3.55 vs. 4.06, respectively) suggesting EAC was targeted towards those with the highest viral loads. We found no difference between groups in terms of the primary short-term outcome, 3-month resuppression among all enrolled (risk difference (RD): À1.7%; 95%CI: À4.3% to 0.9%) ( Table 2 ). However, under 20% of patients had a repeat viral load within 3 months (19.8% intervention, 13.5% control). Overall documented 3-month viral suppression was below 5% in intervention (3.1%) and control (4.8%) arms (RD: 1.7%; 95%CI: À4.3% to 0.9%). Among those with a 3-month viral load, suppression was lower in the intervention vs. control arm (15% vs. 35%, RD: À19.8%; 95% CI: À33.9% to À5.7%).
Because we were concerned the low rate of resuppression might be a data issue, we then looked at the entire population eligible for the intervention with a repeat 3-month viral load at all sites in the intervention period (March 1, 2016 through Sept 30, 2016), rather than just the enrolled cohorts. Among 504 intervention and 430 control site subjects, resuppression was slightly higher in the intervention group (RD 3.0%; 95%CI: À2.7% to 8.8%) (Appendix 1). Using a differences-in-differences approach to control for baseline imbalances, the intervention was associated with a 7.6 percentage point (95% CI: À1.7% to 16.9%) increase in suppression among all those eligible (Appendix 1). Adjusting for clustering and covariates (age, sex, baseline CD4 count, viral load and WHO Stage) the association increased to 8.1% (95% CI: À0.1% to 17.2%). We note that this clinic-wide analysis (which included everyone at the site, not just our enrolled cohort) was not a pre-planned analysis but rather a secondary analysis.
For 12-month viral suppression, about 80% of patients had a repeat viral load. Only about 45% resuppressed, and roughly the same in both arms on follow-up (RD: À0.6%; 95% CI: À7.4% to 6.1%) ( Table 3 ).This did not change when limited to those with a viral load, though the proportion supressed increased slightly (51% vs. 52%, RD: À1.4%; 95% CI: À9.0 to 6.2%). In the period before the intervention, intervention sites had lower resuppression compared to control sites (RD: À1.9%; 95% CI: À4.3% to 0.5%). When accounting for these baseline differences, EAC showed no resuppression benefit (RD: 1.3%; 95% CI: À5.8% to 8.4%) even when adjusting for baseline imbalances and clustering (RD: 1.5%; 95% CI: À14.1% to 17.1%).
Overall 12-month retention was about 75% and also did not differ by arm (RD: À0.3%; 95% CI: À6.1% to 5.5%) (Appendix 2). However, we saw small differences between arms in the pre-period (RD: À3.0%; 95% CI: À5.0% to À1.0%). When controlling for these baseline differences we saw a small, roughly 3% increase in retention associated with the intervention (RD: 2.7%; 95% CI: À3.2% to 8.5%) but confidence intervals were wide. Results changed little when controlling for baseline differences (RD: 2.8%; 95% CI: À7.5% to 13.2%).
Early tracing
Among 403 subjects in the Early Tracing (TRIC) cohort, 56% were below 40 years old, 67% were female and they had a median CD4 count of 212 cells/ll (Table 4) . Median last viral load was low, suggesting many patients being traced were virally supressed prior to missing a visit. Intervention and control groups were balanced with respect to CD4 at ART initiation and log of last viral load. However, intervention patients were younger and eligible for the intervention for substantially longer than the control cohort (85 vs. 29 days).
We saw no evidence TRIC was increasing return rates (Table 5) . Return rates within 3 months were substantially lower among those traced than in the control group (37% vs. 63%), but this is likely because the population targeted for tracing at intervention sites were out of care longer and were therefore less likely to return to care. A more apt comparison is to look at outcomes in the entire population eligible for tracing in both arms and not just those traced or those enrolled for data collection (Appendix 3). Here return rates are higher than observed in our sample and balanced between intervention and control sites (78% vs. 79%; RD: À1.7%; 95% CI: À2.5 to À0.8%). We found no meaningful differences in the preintervention and intervention period (RD 1.6%; 95% CI: 0.8% to 23.1%) such that the simple difference-in-differences analysis showed no overall effect (RD: À3.2%; 95% CI: À8.1% to 1.7%).
We found intervention arm patients had lower 12-month retention than control arm patients (RD: À7.7%; 95% CI: À17.3% to 2.0%) ( Table 6 ). Prior to the intervention period we saw no difference between the arms among eligible patients (RD: À0.5%; 95% CI: À1.3% to 0.3%) but the 12-month retention was higher than in the intervention period. Because we saw little differences between the intervention and pre-intervention period, we saw roughly the same association using difference-in-differences (RD: À7.1%; 95% CI: À15.4% to 1.1%) and when additionally controlling individual level characteristics (RD: À6.8%; 95% CI: À17.7% to 4.8%).
Discussion
As we enter the second decade of large-scale public sector HIV treatment in South Africa, focus has shifted to the complexities of helping patients maintain viral suppression long-term. Many patients persevere on treatment, with a suppressed viral load, without extra attention from health care providers. For others, achieving and maintaining sustained viral suppression is a challenge. For these patients, focused interventions are needed for good clinical outcomes and for reducing infectivity and hence transmission. Differentiated HIV care has been proposed to provide appropriate care to different populations within clinics. The modest body of rigorous evidence on differentiated care to date, however, largely focuses on strategies for stable patients [30] [31] [32] [33] [34] [35] [36] . Far less has been written about strategies for unstable patients, a population much harder to manage. In one of the first randomised trials of approaches to differentiated care implemented by routine service providers, we found limited benefit to both Enhanced Adherence Counselling or Early Tracing compared to standard of care. Our findings suggest that patients who have the most difficulty may require even more intensive interventions if they are to fully suppress. This would include identifying better mechanisms for returning patients to care (e.g. incentives, transportation vouchers, etc.) and for improving adherence (e.g. creating adherence clubs for non-adherent patients targeted at shared barriers to adherence). Enhanced Adherence Counselling showed a 8.1% percentage point increase in viral suppression (95% CI: 0.1% to 17.2%) among those eligible for the intervention who got repeat viral load testing within 3 months using a difference-in-differences approach. It is important to note, however, that very few of those eligible got repeat viral load testing within the prescribed 3-month window. Unfortunately this did not translate to any long-term benefit. This may be explained by the fact that most clinics in South Africa, even in the control arm, should be implementing some form of counselling for those with elevated viral loads, even before EAC began and this could mask any benefits. It is also possible the intervention is not effective, at least as implemented. Counselling interventions are time consuming and EAC may not do much more than current standard of care. Further, our results show it is difficult to get patients to return to care and to ensure they are retested within the 3 month period to determine EAC success. While we have previously found such a targeted approach can be successful for patients with elevated viral loads [37] , without a randomised design it has been hard to argue these associations are causal and these findings suggest they may not be. We do note that delays in viral load testing may have an influence on resuppression given that resistance can develop quickly with NNRTI-based regimens like those being used in South Africa. Further the lack of benefit to EAC may also be due to delays in administering the intervention rather than the intervention itself. We also did not see additional benefit to the TRIC model compared with standard of care tracing practices. In our experience, this is likely due to the fact that tracing has been a difficult intervention to roll-out and monitor, meaning many patients who are traced are not traced soon after missing a visit, as the intervention requires. This was seen in our data. In the intervention cohort we enrolled those who received the intervention as documented in clinic records. The control population was selected randomly from those eligible for the intervention. When comparing the two, we see those in the intervention arm were eligible for tracing longer than in the control arm, suggesting they were less likely to return to care. In addition, akin to adherence counselling, control sites are also supposed to trace lost patients, even if not so early after a patient is lost. Thus, the intervention and control sites are likely implementing very similar interventions leading to no discernible benefit of the TRIC intervention specified in the AGL. Still, tracing is known to be difficult to conduct and returning patients to care is challenging [38] [39] [40] as patients move, some do not wish to return, while others face challenges such as getting time off work, transportation costs and care for family. Without addressing these barriers, it is unlikely tracing will improve outcomes. It is also worth noting that as the intervention is currently designed, far too many patients may become eligible for clinics to practically handle the volume. We found that between 1 March 2016 and 30 September 2016, 59% of patients would have met the "eligibility criteria" for tracing. This may have contributed to the lack of effectiveness.
Although the cluster-randomised design and use of a difference-in-differences approach strengthened our results, the evaluation does have some limitations. First we did not have a pure control group for either intervention, as control sites were delivering some counselling and tracing services. This would bias results towards no effect and might explain why we saw little benefit. Second, in order to not affect retention-based outcomes, the evaluation relied on routine data for outcomes. This led to both missing data and some misclassification of both exposures (some listed as getting the interventions may not have) and outcomes (some missed outcomes may have occurred). Next, we did not have data on some important potential confounders like time on ART or number of elevated viral loads. Also, because of the way data were recorded at sites, while we could identify subjects who received the interventions, we could not determine the total number at a site eligible for the intervention who received one. In addition, we had no data on intervention compliance. We also didn't have data on how much tracing was done or how long it took to contact patients. Further for viral load data, we cannot distinguish between cases where a patient did not return to have a viral load and when a patient did return and a viral load was not done, making it difficult to tell what the appropriate fix would be. In addition, for tracing, while a 5-90 days window is specified in the guidelines for tracing, we know patients were often traced who had already been out of care for some time such that the intervention was much like tracing in the control arm. We also did not fully meet our sample size for each arm and as such may have been underpowered to detect differences. Finally, because we did not control implementation of the interventions, we could not ensure the interventions were targeted to everyone eligible. We suspect they were not, and may have been targeted at those least likely to be affected by the interventions (e.g. if adherence counselling was targeted to those with the biggest barriers to overcome). While we were able to get past this by looking at the larger clinic population, this would also bias towards no effect as not all patients within a clinic who were eligible received the interventions.
Overall, we found a small benefit to EAC in terms of viral suppression within 3 months comparing all eligible patients at intervention and control sites, but not in our pre-specified analysis within our enrolled cohort. We found no benefit over 12 months and no benefit to TRIC as implemented for unstable ART patients in routine care in the South Africa public sector compared against similar interventions provided under standard of care. 
